Our novel mutations in NCOR1, MUC4, and MUC16 genes should be validated in further mechanistic studies and translational studies so that those mutations might serve as predictive biomarkers or therapeutic targets for patients with CDK4/6 inhibitor-resistant breast cancer. This evidence concerns the gene MUC16 and breast cancer.